title: Targeting cyclin-dependent kinases in anti-neoplastic therapy.
abstract: Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.
authors.affiliation: ManRos Therapeutics, Centre de Perharidy, 29680 Roscoff, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Bruyère
authors.forename: Laurent
authors.initials: L
authors.lastname: Meijer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000378:metabolism; D019927:Cyclin E / Q000378:metabolism; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D016274:Oncogene Protein p55(v-myc) / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019927:Cyclin E; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D016274:Oncogene Protein p55(v-myc); D047428:Protein Kinase Inhibitors; D018844:Cyclin-Dependent Kinases